Merck Recalls Liptruzet Tablets Due to Packaging Defects
Merck is recalling Liptruzet tablets because outer packaging defects allowed air and moisture to enter, potentially affecting product effectiveness.
The agency’s classification
FDA (Drugs): Class III
Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 1/5 (Low).
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The recall is classified as FDA Class III and involves packaging defects that may affect product effectiveness, which the rubric defines as typically low severity with no reported injuries.
Plain-English summary
Merck & Co. is recalling specific lots of Liptruzet (ezetimibe and atorvastatin) tablets, 10 mg/40 mg, due to packaging defects. The recall involves 30-count and 90-count blister packs distributed nationwide and in Puerto Rico.
The recall was initiated because some of the outer laminate foil pouches allowed air and moisture to enter. This exposure could potentially decrease the effectiveness of the medication or change its characteristics.
Consumers with these specific products should contact their healthcare provider or pharmacist for guidance. The affected lots are identified by specific expiration dates and lot numbers listed in the recall documentation.
The recalled product
- Product
- Liptruzet (ezetimibe and atorvastin) tablets,10 mg/40 mg, a) 30 count blister (NDC 66582-322-30), b) 90 count blister (NDC 66582-322-54), Rx only, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ 08889
- Manufacturer
- Merck & Co Inc
- Category
- Drug — Prescription Medication
- Affected units
- 36,493
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (12)
- a) Liptruzet 10/40mg 30 count
- 346304
- 346342
- 350256
- 353107
- 353108
- 353109
- Exp. 06/14
- 353110
- Exp.12/14 b) Liptruzet 10/40mg 90 count 346382
- 353186
- Exp.12/14.
Distribution
Part of a larger recall action
This product is one of 4 recalled by Merck & Co Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same manufacturer · Merck & Co Inc
See all →- ModerateBelsomra 10 mg tablets failed dissolution, which may delay sleep onset
FDA (Drugs) · 2025-08-20
- LowMerck Recalls Liptruzet Tablets Due to Packaging Defects
FDA (Drugs) · 2014-05-14
- LowMerck Recalls Liptruzet Tablets Due to Packaging Defects
FDA (Drugs) · 2014-05-14
- LowMerck Recalls Liptruzet Tablets Due to Defective Outer Packaging
FDA (Drugs) · 2014-05-14
Same hazard · packaging defect
See all →- HighEmbosphere Microspheres Recalled Due to Packaging Sterility Concerns
FDA (Devices) · 2026-10-07
- ModerateAmneal Recalls Estradiol Gel Packets Due to Empty or Partially Full Containers
FDA (Drugs) · 2026-10-07
- HighCardinal Health Recalls Presource Convenience Kits Due to Seal Defects
FDA (Devices) · 2026-09-30
- ModerateAVID Medical Recalls Halyard IV Start Kits Due to Packaging Seal Issues
FDA (Devices) · 2026-09-30
- HighCardinal Health Recalls Presource Convenience Kits Due to Potential Seal Defects
FDA (Devices) · 2026-09-30
Similar recalls
- SevereMerck Recalls Vytorin Tablets Due to Foreign Tablet Presence
FDA (Drugs) · 2015-10-14
- ModeratePfizer Recalls Caduet Tablets Due to Defective Bottle Seals
FDA (Drugs) · 2020-02-19
- SevereImpax Recalls Lamotrigine Tablets Due to Labeling Mixup
FDA (Drugs) · 2016-12-28
- ModerateAmerican Health Packaging Recalls Azithromycin Tablets Due to CGMP Deviations
FDA (Drugs) · 2015-07-15
- SevereRemedyRepack Recalls Losartan 50mg Tablets Due to Impurity
FDA (Drugs) · 2019-04-17
- ModerateWockhardt Recalls Azithromycin Tablets Due to Complaint Investigation Failures
FDA (Drugs) · 2015-07-29